Financial Astrology of Zimmer Holdings, Inc.

FINANCIAL ASTROLOGY

First Trade Date for Zimmer Holdings, Inc.

Company Name	First Trade Date (yyyy-mm-dd)
Zimmer Holdings, Inc.	2001-07-25

Company Name	Symbol
Zimmer Holdings, Inc.	ZMH
History and Business of Company (this information may include date of incorporation)
Zimmer Holdings, Inc., a Delaware corporation, is a global leader in the design, development, manufacture and marketing of reconstructive orthopaedic implants, including joint and dental, spinal implants, and trauma products and related orthopaedic surgical products. The Company is headquartered in Warsaw, Indiana. Unless the context requires otherwise, the term "Zimmer" and "Company" refer to Zimmer Holdings, Inc. and all of its subsidiaries. On October 2, 2003, the Company announced the closing of its exchange offer for Centerpulse AG ("Centerpulse"), a leading global orthopaedic medical device company headquartered in Switzerland that services the reconstructive joint, spine and dental implant markets. The Centerpulse acquisition provided the Company with a leading position in the European orthopaedic reconstructive implant market and a platform in the fast growing spinal market. The aggregate consideration paid by the Company for Centerpulse and InCentive Capital AG, a company that beneficially owned 18.3 percent of the issued Centerpulse shares ("InCentive"), excluding direct acquisition costs, was approximately $3.4 billion, consisting of approximately 44.5 million shares of Company common stock (valued at approximately $2.2 billion) and approximately $1.2 billion in cash. The Company used its $1.75 billion senior credit facility to finance the cash component. On March 2, 2004, the Company entered into an Amended and Restated Agreement and Plan of Merger (the "Merger Agreement") relating to the acquisition of Implex Corp. ("Implex"). Pursuant to the terms of the Merger Agreement, the shareholders of Implex will receive an initial cash payment and deferred, contingent earn-out payments, also payable in cash. In 2000, the Company entered into an exclusive, worldwide strategic alliance for commercialization of Implex's innovative Hedrocel(r)1 biomaterial, which the Company has marketed as Trabecular Metal(tm) Technology. The proposed merger is an anticipated outcome of the Company's alliance relationship with Implex. The acquisition is expected to close in April of 2004. Zimmer was incorporated on January 12, 2001 as a wholly-owned subsidiary of Bristol-Myers Squibb Company ("Bristol-Myers"). Zimmer, Inc., a predecessor founded in 1927, was acquired by Bristol-Myers in 1972 and along with its wholly-owned subsidiaries and certain other of Bristol-Myers' operations comprised the orthopaedics business of Bristol-Myers. On August 6, 2001, the Company was spun off from Bristol-Myers and became an independent public company.

IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.